Loading
ESG401 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for triple-negative breast cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
ESG401 is an investigational agent whose form is not stated in the registry developed by Qilu Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06732323 (A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer) and NCT06383767 (A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer), in triple-negative breast cancer and HR-positive / HER2-negative breast cancer. The largest, NCT06732323, plans to enrol 504 participants with primary completion expected 2027-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.ESG401's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ESG401" OR ABSTRACT:"ESG401") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ESG401, not a curated reading list.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.